Nuvalent NSCLC treatment granted FDA orphan designation

Nuvalent was granted FDA orphan designation for its treatment of ALK-positive, ROS1-positive, and LTK-positive non-small cell lung cancer, or NSCLC, according to a post to the agency’s website. Reference Link